Karyopharm Therapeutics (NASDAQ:KPTI) Stock Bumped Down to “Neutral” by Rodman & Renshaw

Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by analysts at Rodman & Renshaw from a “buy” rating to a “neutral” rating in a research note issued to investors on Monday, Benzinga reports.

Other equities research analysts also recently issued research reports about the stock. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $16.00 price target on shares of Karyopharm Therapeutics in a research note on Tuesday, July 21st. Wall Street Zen lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings lowered Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 24th. HC Wainwright lowered Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a research report on Friday, July 31st. Finally, Robert W. Baird lowered shares of Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a report on Friday, July 31st. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $11.50.

Karyopharm Therapeutics Trading Down 83.2%

NASDAQ KPTI traded down $0.55 on Monday, hitting $0.11. 35,936,290 shares of the company traded hands, compared to its average volume of 1,565,254. The company has a market capitalization of $2.52 million, a price-to-earnings ratio of -0.01 and a beta of 1.04. Karyopharm Therapeutics has a 52-week low of $0.09 and a 52-week high of $10.99. The business’s 50 day moving average price is $1.22 and its 200-day moving average price is $6.02.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.95). The firm had revenue of $33.43 million for the quarter, compared to analysts’ expectations of $32.19 million. As a group, sell-side analysts predict that Karyopharm Therapeutics will post -4.70 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KPTI. Commodore Capital LP purchased a new stake in Karyopharm Therapeutics during the 1st quarter worth approximately $10,862,000. Avidity Partners Management LP raised its holdings in shares of Karyopharm Therapeutics by 244.6% during the first quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock valued at $2,583,000 after acquiring an additional 329,175 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Karyopharm Therapeutics by 75.9% during the first quarter. Renaissance Technologies LLC now owns 105,414 shares of the company’s stock valued at $587,000 after acquiring an additional 45,500 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Karyopharm Therapeutics during the second quarter valued at approximately $623,000. Finally, Royal Bank of Canada lifted its position in shares of Karyopharm Therapeutics by 4.1% in the first quarter. Royal Bank of Canada now owns 60,399 shares of the company’s stock valued at $336,000 after acquiring an additional 2,399 shares in the last quarter. 66.44% of the stock is owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company’s research centers on selective inhibitors of nuclear export (SINE), a class of compounds designed to interfere with the transport of tumor-suppressing proteins and other molecules in cancer cells.

Karyopharm’s leading product is selinexor, marketed in the United States as XPOVIO and in certain international markets as NEXPOVIO.